Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study.
Penner J, Abdel-Mannan O, Grant K, Maillard S, Kucera F, Hassell J, Eyre M, Berger Z, Hacohen Y, Moshal K; GOSH PIMS-TS MDT Group. Penner J, et al. Lancet Child Adolesc Health. 2021 Jul;5(7):473-482. doi: 10.1016/S2352-4642(21)00138-3. Epub 2021 May 25. Lancet Child Adolesc Health. 2021. PMID: 34043958
Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme.
Ghimire B, Maroni R, Vulkan D, Shah Z, Gaynor E, Timoney M, Jones L, Arvanitis R, Ledson M, Lukehirst L, Rutherford P, Clarke F, Gardner K, Marcus MW, Hill S, Fidoe D, Mason S, Smith SG, Quaife SL, Fitzgerald K, Poirier V, Duffy SW, Field JK. Ghimire B, et al. Among authors: gaynor e. Lung Cancer. 2019 Aug;134:66-71. doi: 10.1016/j.lungcan.2019.05.026. Epub 2019 May 29. Lung Cancer. 2019. PMID: 31319997
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Kennedy NA, et al. Gut. 2021 May;70(5):865-875. doi: 10.1136/gutjnl-2021-324388. Epub 2021 Mar 22. Gut. 2021. PMID: 33753421
SARS-CoV-2 and the Gastrointestinal Tract in Children.
Puoti MG, Rybak A, Kiparissi F, Gaynor E, Borrelli O. Puoti MG, et al. Among authors: gaynor e. Front Pediatr. 2021 Feb 22;9:617980. doi: 10.3389/fped.2021.617980. eCollection 2021. Front Pediatr. 2021. PMID: 33692973 Free PMC article. Review.
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
Chanchlani N, Lin S, Auth MK, Lee CL, Robbins H, Looi S, Murugesan SV, Riley T, Preston C, Stephenson S, Cardozo W, Sonwalkar SA, Allah-Ditta M, Mansfield L, Durai D, Baker M, London I, London E, Gupta S, Di Mambro A, Murphy A, Gaynor E, Jones KDJ, Claridge A, Sebastian S, Ramachandran S, Selinger CP, Borg-Bartolo SP, Knight P, Sprakes MB, Burton J, Kane P, Lupton S, Fletcher A, Gaya DR, Colbert R, Seenan JP, MacDonald J, Lynch L, McLachlan I, Shields S, Hansen R, Gervais L, Jere M, Akhtar M, Black K, Henderson P, Russell RK, Lees CW, Derikx LAAP, Lockett M, Betteridge F, De Silva A, Hussenbux A, Beckly J, Bendall O, Hart JW, Thomas A, Hamilton B, Gordon C, Chee D, McDonald TJ, Nice R, Parkinson M, Gardner-Thorpe H, Butterworth JR, Javed A, Al-Shakhshir S, Yadagiri R, Maher S, Pollok RCG, Ng T, Appiahene P, Donovan F, Lok J, Chandy R, Jagdish R, Baig D, Mahmood Z, Marsh L, Moss A, Abdulgader A, Kitchin A, Walker GJ, George B, Lim YH, Gulliver J, Bloom S, Theaker H, Carlson S, Cummings JRF, Livingstone R, Beale A, Carter JO, Bell A, Coulter A, Snook J, Stone H, Kennedy NA, Goodhand JR, Ahmad T; IMSAT study investigators. Chanchlani N, et al. Among authors: gaynor e. Aliment Pharmacol Ther. 2022 Oct;56(8):1250-1263. doi: 10.1111/apt.17170. Epub 2022 Aug 29. Aliment Pharmacol Ther. 2022. PMID: 36039036 Free PMC article.
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, McDonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones GR, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T; CLARITY IBD study. Lin S, et al. Nat Commun. 2022 Mar 16;13(1):1379. doi: 10.1038/s41467-022-28517-z. Nat Commun. 2022. PMID: 35296643 Free PMC article.
Erratum to "Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme" [Lung Cancer 134 (August) (2019) 66-71].
Ghimire B, Maroni R, Vulkan D, Shah Z, Gaynor E, Timoney M, Jones L, Arvanitis R, Ledson M, Lukehirst L, Rutherford P, Clarke F, Gardner K, Marcus MW, Hill S, Fidoe D, Mason S, Smith SG, Quaife SL, Fitzgerald K, Poirier V, Duffy SW, Field JK. Ghimire B, et al. Among authors: gaynor e. Lung Cancer. 2020 Jan;139:224. doi: 10.1016/j.lungcan.2019.10.007. Epub 2019 Nov 2. Lung Cancer. 2020. PMID: 31690469 No abstract available.
154 results